Skip to main
SRRK

SRRK Stock Forecast & Price Target

SRRK Analyst Ratings

Based on 12 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Scholar Rock Holding is facing potential risks such as the failure of its pipeline candidates to show efficacy and competition from alternative approaches. Additionally, the broad adoption of gene therapies in the targeted patient population could limit the company's growth potential. However, if the Catalent site is replaced and the full data/CMC package is approved in a timely manner, and if regulatory hurdles are successfully addressed, this could lead to increased investor confidence and a positive outlook for the company's stock.

Bears say

Scholar Rock Holding is expected to face challenges in the short term, due to the recent classification of its second fill-finish facility by the FDA, but its strong pipeline of therapies for rare neuromuscular diseases remains a long-term growth driver. Despite the potential delays in obtaining approvals for its therapies in both the US and EU markets, the company's proactive approach of having a two-site redundancy and progress in the regulatory review of the second facility, shows strong management capabilities and a commitment to its pipeline. However, investors should remain cautious and monitor any updates on the regulatory timeline and potential impact on the company's commercial launch and market potential.

SRRK has been analyzed by 12 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Scholar Rock Holding Corp (SRRK) Forecast

Analysts have given SRRK a Buy based on their latest research and market trends.

According to 12 analysts, SRRK has a Buy consensus rating as of Aug 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $58.42, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $58.42, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Scholar Rock Holding Corp (SRRK)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.